In a randomized trial in Africa, intramuscular depot medroxyprogesterone did not increase HIV acquisition compared with the copper IUD or levonorgestrel implant.
Observational studies in sub-Saharan Africa have suggested that intramuscular depot medroxyprogesterone (DMPA-IM) can increase women's risk for HIV acquisition, raising concerns about this highly effective and safe long-acting reversible contraceptive (LARC; NEJM JW Womens Health Nov 2017 and MMWR Morb Mortal Wkly Rep 2017; 66:990). Now, investigators have conducted a randomized, open-label trial of DMPA-IM, copper intrauterine devices (IUDs), and levonorgestrel implants in 7829 HIV-negative women (median age, 23) seeking contraceptives in Eswatini, Kenya, South Africa, and Zambia. Participants were followed for ≤18 months.
A total of 397 women acquired HIV infection. Incidence was similar in all three groups (DMPA-IM, 4.19/100 woman-years; …
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)